Novel therapeutic approach to systolic heart failure (HFrEF) management: omecamtiv mecarbil
█ Review
DOI: 10.26430/CHUNGARICA.2021.51.2.118
Authors:
Ráduly Arnold Péter1, Tóth Attila1, Papp Zoltán1, Borbély Attila1, 2
1Debreceni Egyetem, Általános Orvostudományi Kar, 1Kardiológiai Intézet, Klinikai Fiziológiai Tanszék,
2Kardiológiai Intézet, Kardiológiai Tanszék, Debrecen
Levelezési cím:
Dr. Borbély Attila, Debreceni Egyetem, Általános Orvostudományi Kar, Kardiológiai Intézet, Kardiológiai Tanszék
4032 Debrecen Móricz Zsigmond krt. 22. E-mail: borbelya@med.unideb.hu
Summary
Novel therapeutic approach to systolic heart failure (HFrEF) management: omecamtiv mecarbil
Heart failure remains a disease with very high mortality and morbidity. Agents that improve cardiac contractile function are of paramount importance in the treatment of heart failure with reduced ejection fraction (HFrEF). Only few drugs are available to improve contractility in a safe manner (i.e. in the absence of increased myocardial oxygen and energy demands). Particular attention surrounded the direct modulation of the actin-myosin crossbridge cycle in the past decade. The first drug candidate with such a mechanism of action to reach a phase III clinical trial is omecamtiv mecarbil. The purpose of this review is to summarize the knowledge of omecamtiv mecarbil that is also relevant to clinical practice, as well as to present the main results of the recently published GALACTIC-HF clinical trial.
ISSUE: CARDIOLOGIA HUNGARICA | 2021 | VOLUME 51, ISSUE 2
click here to read the full article |
click here to read the pdf |